Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease.

Inflammation occurs as a result of exposure of tissues and organs to harmful stimuli such as microbial pathogens, irritants, or toxic cellular components. The primary physical manifestations of inflammation are redness, swelling, heat, pain, and loss of function to the affected area. These processes involve the major cells of the immune system, including monocytes, macrophages, neutrophils, basophils, dendritic cells, mast cells, T-cells, and B-cells. However, examination of a range of inflammatory lesions demonstrates the presence of specific leukocytes in any given lesion. That is, the inflammatory process is regulated in such a way as to ensure that the appropriate leukocytes are recruited. These events are in turn controlled by a host of extracellular molecular regulators, including members of the cytokine and chemokine families that mediate both immune cell recruitment and complex intracellular signalling control mechanisms that characterise inflammation. This review will focus on the role of the main cytokines, chemokines, and their receptors in the pathophysiology of auto-inflammatory disorders, pro-inflammatory disorders, and neurological disorders involving inflammation.

[1]  D. MacEwan TNF receptor subtype signalling: differences and cellular consequences. , 2002, Cellular signalling.

[2]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[3]  H. Yazici,et al.  Acute phase response in familial Mediterranean fever , 2002, Annals of the rheumatic diseases.

[4]  D. Männel,et al.  The TNFTNF Receptor System , 2002 .

[5]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.

[6]  E. Bézard,et al.  Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease , 2004, The European journal of neuroscience.

[7]  S. Akıncı,et al.  Serum sIL-2r, IL-6, IL-10 and TNF-α level in familial Mediterranean fever patients , 2003, Clinical Rheumatology.

[8]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[9]  W. Brück,et al.  Additive microglia-mediated neuronal injury caused by amyloid-β and bacterial TLR agonists in murine neuron-microglia co-cultures quantified by an automated image analysis using cognition network technology. , 2012, Journal of Alzheimer's disease : JAD.

[10]  D. Largaespada,et al.  Lymphotactin: a cytokine that represents a new class of chemokine. , 1994, Science.

[11]  L. Mayer,et al.  Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease , 2010, Expert review of clinical immunology.

[12]  G. Hitman,et al.  Proinflammatory action of the antiinflammatory drug infliximab in TNF-receptor associated periodic syndrome , 2009 .

[13]  J. Gauldie,et al.  IFNβ2/BSF2/IL‐6 Is the Monocyte‐derived HSF That Regulates Receptor‐specific Acute Phase Gene Regulation in Hepatocytes a , 1989, Annals of the New York Academy of Sciences.

[14]  K. Suk,et al.  IFN-γ/TNF-α Synergism as the Final Effector in Autoimmune Diabetes: A Key Role for STAT1/IFN Regulatory Factor-1 Pathway in Pancreatic β Cell Death1 , 2001, The Journal of Immunology.

[15]  I. Ceccherini,et al.  A novel mutation in the CIAS1/NLRP3 gene associated with an unexpected phenotype of cryopyrin-associated periodic syndromes. , 2014, Clinical and experimental rheumatology.

[16]  T. Di Paolo,et al.  Differential Protective Properties of Estradiol and Tamoxifen against Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity in Mice , 2006, Neuroendocrinology.

[17]  S. Segerer,et al.  The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity , 2009, Nature Immunology.

[18]  D. Zemer,et al.  Activation of the cytokine network in familial Mediterranean fever. , 1999, The Journal of rheumatology.

[19]  N. Borregaard,et al.  Neutrophil granules and secretory vesicles in inflammation. , 2003, Microbes and infection.

[20]  N. Osada,et al.  Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history , 2012, Genes to cells : devoted to molecular & cellular mechanisms.

[21]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[22]  T. Kishimoto IL-6: from its discovery to clinical applications. , 2010, International immunology.

[23]  Terry Farrah,et al.  The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.

[24]  J. Lafitte,et al.  Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. , 2001, The Journal of allergy and clinical immunology.

[25]  C. Luo,et al.  CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. , 2013, American journal of physiology. Endocrinology and metabolism.

[26]  M. Haneklaus,et al.  Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. , 2013, Current opinion in immunology.

[27]  M. Zeher,et al.  Serum and urinary cytokine levels of SLE patients. , 2012, Die Pharmazie.

[28]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[29]  M. Leirisalo-Repo The present knowledge of the inflammatory process and the inflammatory mediators. , 1994, Pharmacology & toxicology.

[30]  M. Sporn,et al.  The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection , 2008, Journal of Neuroinflammation.

[31]  A. Członkowska,et al.  Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Immunopharmacology.

[32]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Chromy,et al.  Amyloid-β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release , 1998, Brain Research.

[34]  M. Pras,et al.  Clinical disease among patients heterozygous for familial Mediterranean fever. , 2009, Arthritis and rheumatism.

[35]  D. Häussinger,et al.  Caspase-mediated cleavage of the signal-transducing IL-6 receptor subunit gp130. , 2008, Archives of biochemistry and biophysics.

[36]  P Barton,et al.  The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. , 2004, Health technology assessment.

[37]  P. Taupin Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells , 2008, International journal of medical sciences.

[38]  Zheng‐gang Liu,et al.  The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors , 2008, Nature Immunology.

[39]  Yoshiya Tanaka Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? , 2012, Annals of the rheumatic diseases.

[40]  C. Abraham Reactive astrocytes and α1-antichymotrypsin in Alzheimer’s disease ☆ ☆ Supported by the NIH and the Alzheimer’s Association. , 2001, Neurobiology of Aging.

[41]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[42]  A. Sidhu,et al.  Inflammation and Parkinson's disease. , 2002, Current drug targets. Inflammation and allergy.

[43]  Rena Li,et al.  Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain , 1997, Brain Research.

[44]  M. Eberhardson,et al.  Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. , 2013, Clinical immunology.

[45]  M. Pillinger,et al.  Interleukin-6 in the pathogenesis of rheumatoid arthritis. , 2007, Bulletin of the NYU hospital for joint diseases.

[46]  Caroline A Sabin,et al.  Natural history and outcome in systemic AA amyloidosis. , 2007, The New England journal of medicine.

[47]  M. Matthay,et al.  Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. , 1992, The American review of respiratory disease.

[48]  Shyamasree Ghosh,et al.  C-reactive protein and the biology of disease , 2013, Immunologic Research.

[49]  Y Agid,et al.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Wenjie Xie,et al.  Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease , 2001, The Journal of Neuroscience.

[51]  Fiona C. Kimberley,et al.  Disease causing mutations in the TNF and TNFR superfamilies: Focus on molecular mechanisms driving disease. , 2011, Trends in molecular medicine.

[52]  M. Miura,et al.  Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1β, and Expression of Caspase-11 in Mice* , 2004, Journal of Biological Chemistry.

[53]  D. Kastner,et al.  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. , 2008, Arthritis and rheumatism.

[54]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[55]  Sudhir Gupta,et al.  Tumor necrosis factor-α-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signaling molecules , 2002, Experimental Gerontology.

[56]  C. Hawkey,et al.  Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. , 1992, Clinical science.

[57]  H. Joller-jemelka,et al.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.

[58]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[59]  E. Ben-Chetrit,et al.  Familial mediterranean fever and Behçet's disease--are they associated? , 2002, The Journal of rheumatology.

[60]  M. Satoh,et al.  Apoptosis of cultured microglia by the deprivation of macrophage colony-stimulating factor , 1996, Neuroscience Research.

[61]  C. Ware,et al.  TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. , 1998, Journal of immunology.

[62]  A. Bowie,et al.  Activation of host pattern recognition receptors by viruses. , 2010, Current opinion in microbiology.

[63]  L. Mayer,et al.  Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update , 2013, Expert review of clinical immunology.

[64]  M. Delgado,et al.  Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[65]  James C. Powell,et al.  Interleukin-1 Receptor Type 1 Is a Substrate for γ-Secretase-dependent Regulated Intramembrane Proteolysis* , 2009, Journal of Biological Chemistry.

[66]  M. Baggiolini,et al.  Monocyte chemotactic proteins MCP‐1, MCP‐2, and MCP‐3 are major attractants for human CD4+ and CD8+ T lymphocytes , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  G. Gualdi,et al.  Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra. , 2013, Dermatology online journal.

[68]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[69]  H. Ichinose,et al.  Cytokines in Parkinson’s Disease , 2000 .

[70]  K. Garber Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market , 2013, Nature Biotechnology.

[71]  Andrew G. D. Bean,et al.  TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection1 , 2002, The Journal of Immunology.

[72]  G. Arendash,et al.  Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease , 2009, Glia.

[73]  B. Bradt,et al.  Constitutive expression of proinflammatory complement components by subsets of neurons in the central nervous system , 2002, Journal of Neuroimmunology.

[74]  G. Yancopoulos,et al.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. , 2008, Arthritis and rheumatism.

[75]  R. Powell,et al.  Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. , 1997, Mayo Clinic proceedings.

[76]  M. Johnstone,et al.  A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced , 1999, Journal of Neuroimmunology.

[77]  L. Ginsberg,et al.  Neurologic manifestations of the cryopyrin-associated periodic syndrome , 2010, Neurology.

[78]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. , 1996, Nature.

[79]  Y. Iwakura,et al.  A role for leukocyte-derived IL-1RA in DC homeostasis revealed by increased susceptibility of IL-1RA-deficient mice to cutaneous leishmaniasis. , 2011, The Journal of investigative dermatology.

[80]  E. Posse de Chaves,et al.  Aβ Internalization by Neurons and Glia , 2011, International journal of Alzheimer's disease.

[81]  M. Feldmann,et al.  Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us? , 2010, The Journal of Immunology.

[82]  S. Hunot,et al.  Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.

[83]  T. Town,et al.  Neuronal expression of CD22: Novel mechanism for inhibiting microglial proinflammatory cytokine production , 2004, Glia.

[84]  R. Vassar,et al.  The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis , 2011, Journal of Neuroinflammation.

[85]  A. Hamzaoui,et al.  Levels of IL‐15 in Serum and Cerebrospinal Fluid of Patients with Behçet's Disease , 2006, Scandinavian journal of immunology.

[86]  R. Vink,et al.  Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. , 2009, Recent patents on CNS drug discovery.

[87]  C. von Kalle,et al.  Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. , 1991, Blood.

[88]  Sara Hall,et al.  Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment , 2013, Brain, Behavior, and Immunity.

[89]  R. Vaughan,et al.  Behçet’s disease: from Hippocrates to the third millennium , 2003, The British journal of ophthalmology.

[90]  P. Scheurich,et al.  Coexpression of the human TNF receptors TR60 and TR80 in insect cells: analysis of receptor complex formation. , 1994, Lymphokine and cytokine research.

[91]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[92]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[93]  Wan-Wan Lin,et al.  Silymarin protects dopaminergic neurons against lipopolysaccharide‐induced neurotoxicity by inhibiting microglia activation , 2002, The European journal of neuroscience.

[94]  M. Thelen,et al.  Dancing to the tune of chemokines , 2001, Nature Immunology.

[95]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[96]  D. Ota,et al.  Angiogenic Effects of Interleukin 8 (CXCL8) in Human Intestinal Microvascular Endothelial Cells Are Mediated by CXCR2* , 2003, The Journal of Biological Chemistry.

[97]  R. Mrak,et al.  Interleukin-1, neuroinflammation, and Alzheimer’s disease , 2001, Neurobiology of Aging.

[98]  Howard E. Gendelman,et al.  Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[99]  E. Hauben,et al.  SPPL2a and SPPL2b promote intramembrane proteolysis of TNFα in activated dendritic cells to trigger IL-12 production , 2006, Nature Cell Biology.

[100]  B. Botterman,et al.  Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.

[101]  M. Krane,et al.  Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. , 2006, American journal of respiratory and critical care medicine.

[102]  J. Casanova,et al.  Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. , 2011, Annual review of immunology.

[103]  Kate Schroder,et al.  The NLRP3 Inflammasome: A Sensor for Metabolic Danger? , 2010, Science.

[104]  R. Sartor Cytokines in Intestinal Inflammation: Clinical Considerations , 1994 .

[105]  M. Karow,et al.  The Eotaxin Chemokines and CCR3 Are Fundamental Regulators of Allergen-Induced Pulmonary Eosinophilia1 , 2005, The Journal of Immunology.

[106]  S. Akira,et al.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.

[107]  J. Verhoef,et al.  Amyloid-β-induced chemokine production in primary human macrophages and astrocytes , 2002, Journal of Neuroimmunology.

[108]  B. Medoff,et al.  IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. , 2002, Journal of immunology.

[109]  Mark P. Mattson,et al.  NF-κB in the Survival and Plasticity of Neurons , 2005, Neurochemical Research.

[110]  A. Plebani,et al.  Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis , 2010, Annals of the rheumatic diseases.

[111]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[112]  T. Wright,et al.  Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A , 1999 .

[113]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[114]  Hong-Wei Sun,et al.  Homeostatic Tissue Responses in Skin Biopsies from NOMID Patients with Constitutive Overproduction of IL-1β , 2012, PloS one.

[115]  M. Pepys,et al.  Acute phase response and evolution of familial Mediterranean fever. , 1999, Lancet.

[116]  Saumya Das,et al.  Effect of cytokines, dexamethazone and the A/T-signal peptide polymorphism on the expression of alpha1-antichymotrypsin in astrocytes: significance for Alzheimer's disease , 2001, Neurochemistry International.

[117]  L. Piccio,et al.  Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. , 2000, Immunity.

[118]  İ. Tuğal-Tutkun,et al.  Pro-inflammatory cellular immune response in Behçet’s disease , 2007, Rheumatology International.

[119]  M. Sporn,et al.  Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription , 2009, PloS one.

[120]  K. Nadeau,et al.  XCL1 Enhances Regulatory Activities of CD4+CD25highCD127low/− T Cells in Human Allergic Asthma1 , 2008, The Journal of Immunology.

[121]  J. Lindenmann,et al.  Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[122]  P. Lipsky,et al.  Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis , 2009, Arthritis research & therapy.

[123]  Han-Chang Huang,et al.  Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[124]  E. Hirsch,et al.  Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease , 2002, Journal of neurochemistry.

[125]  W. Kohr,et al.  Human tumor necrosis factor. , 1985, Methods in enzymology.

[126]  P. Hawkins,et al.  Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. , 2003, The New England journal of medicine.

[127]  M. Pepys,et al.  Acute phase response and evolution of familial Mediter ranean fever , 1999, The Lancet.

[128]  E. Tolosa,et al.  Parkinson disease: New guidelines for diagnosis of Parkinson disease , 2013, Nature Reviews Neurology.

[129]  D. Farfara,et al.  Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease , 2008, Journal of cellular and molecular medicine.

[130]  M. Tansey,et al.  Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.

[131]  B. Molnár,et al.  Changes of the cytokine profile in inflammatory bowel diseases. , 2012, World journal of gastroenterology.

[132]  J. Lindenmann,et al.  Virus interference. I. The interferon. , 1987, Proceedings of the Royal Society of London. Series B, Biological sciences.

[133]  J. Cano,et al.  Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system , 2004, Neurobiology of Disease.

[134]  M. Delgado,et al.  Vasoactive intestinal peptide prevents activated microglia‐induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[135]  D. Perl,et al.  Aggresome‐related biogenesis of Lewy bodies , 2002, The European journal of neuroscience.

[136]  W. Friedman Cytokines Regulate Expression of the Type 1 Interleukin-1 Receptor in Rat Hippocampal Neurons and Glia , 2001, Experimental Neurology.

[137]  M. Mattson,et al.  Roles for NF-kappaB in nerve cell survival, plasticity, and disease. , 2006, Cell death and differentiation.

[138]  C. Abraham Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. , 2001, Neurobiology of aging.

[139]  H. Koeffler,et al.  Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. , 2000, Blood.

[140]  Ole Isacson,et al.  Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease , 2004, Journal of Neuroinflammation.

[141]  L. Lue,et al.  Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease , 2001, Neurochemistry International.

[142]  J. Julien,et al.  Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease , 2006, Neuron.

[143]  M. Duvdevani,et al.  Expansion of γδ T-cells in Behçet's disease: Role of disease activity and microbial flora in oral ulcers , 2003 .

[144]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[145]  W. Le,et al.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.

[146]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[147]  R. Valentine,et al.  Virus interference. II. Some properties of interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[148]  M. Feldmann,et al.  Anti-TNF Therapy. , 2016, Microbiology spectrum.

[149]  K. Rajarathnam,et al.  Diverging Mechanisms of Activation of Chemokine Receptors Revealed by Novel Chemokine Agonists , 2011, PloS one.

[150]  R M Siegel,et al.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. , 2000, Science.

[151]  J. Cano,et al.  The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. , 2002, Journal of neurochemistry.

[152]  M. Baggiolini,et al.  Neutrophil activation and the effects of interleukin-8/neutrophil-activating peptide 1 (IL-8/NAP-1). , 1992, Cytokines.

[153]  A. Peled,et al.  Critical Involvement of the Chemotactic Axis CXCR4/Stromal Cell-Derived Factor-1α in the Inflammatory Component of Allergic Airway Disease , 2000, The Journal of Immunology.

[154]  A. Cope,et al.  Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints , 1992, European journal of immunology.

[155]  A. Antonini,et al.  EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease , 2013, European journal of neurology.

[156]  C. Kaltschmidt,et al.  Signaling via NF-?B in the nervous system , 2005 .

[157]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[158]  M. Baggiolini Chemokines in pathology and medicine , 2001, Journal of internal medicine.

[159]  M. Alonso,et al.  Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells , 2012, Journal of neuroscience research.

[160]  Jau-Shyong Hong,et al.  Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease , 2011, Parkinson's disease.

[161]  T. Chase,et al.  NF-κB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53 , 2007, Brain Research.

[162]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[163]  H. Rosenzweig,et al.  Impact of IL-1 signalling on experimental uveitis and arthritis , 2012, Annals of the rheumatic diseases.

[164]  K. Matsushima,et al.  Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. , 1989, Journal of immunology.

[165]  C. Elson,et al.  Experimental models of inflammatory bowel disease. , 1995, Gastroenterology.

[166]  J. Lannigan,et al.  Analysis of CD25hiCD4+ "regulatory" T-cell subtypes in atopic dermatitis reveals a novel T(H)2-like population. , 2008, The Journal of allergy and clinical immunology.

[167]  John Hardy,et al.  Parkinson's disease , 2009, The Lancet.

[168]  E. Sohar,et al.  [Familial Mediterranean fever]. , 1955, Acta geneticae medicae et gemellologiae.

[169]  W. Arend,et al.  Biological role of interleukin 1 receptor antagonist isoforms , 2000, Annals of the rheumatic diseases.

[170]  B. Liu,et al.  Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[171]  G. Hitman,et al.  A novel TNFRSF1A splice mutation associated with increased nuclear factor κappaB (NF-κB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS) , 2007, Annals of the rheumatic diseases.

[172]  H. Hoffman Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). , 2009, Expert opinion on biological therapy.

[173]  R. Flores,et al.  Sustained IL‐1α, IL‐4, and IL‐6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus , 2008, Pediatric diabetes.

[174]  S. M. McFarlane,et al.  Differential activation of nuclear factor‐κB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly , 2002, FEBS letters.

[175]  Valentin A. Pavlov,et al.  The cholinergic anti-inflammatory pathway , 2005, Brain, Behavior, and Immunity.

[176]  E. Sohar,et al.  FAMILIAL MEDITERRANEAN FEVER , 1959, Definitions.

[177]  Marlene Wolf,et al.  Chemokines: multiple levels of leukocyte migration control. , 2004, Trends in immunology.

[178]  M. Mattson,et al.  Roles for NF-κB in nerve cell survival, plasticity, and disease , 2006, Cell Death and Differentiation.

[179]  H. Arias,et al.  The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.

[180]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[181]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[182]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[183]  B. Koller,et al.  Genetic Loss of Murine Pyrin, the Familial Mediterranean Fever Protein, Increases Interleukin-1β Levels , 2012, PloS one.

[184]  P. Venge,et al.  Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. , 1996, The Journal of allergy and clinical immunology.

[185]  J. Bijzet,et al.  Specific glycosylation of α1-acid glycoprotein characterises patients with familial Mediterranean fever and obligatory carriers of MEFV , 2001, Annals of the rheumatic diseases.

[186]  J. Cano,et al.  The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐α, IL‐1β and IFN‐γ , 2002 .

[187]  K. Biber,et al.  Neuron-microglia signaling: Chemokines as versatile messengers , 2008, Journal of Neuroimmunology.

[188]  J. Nutt,et al.  Neuroimmunophilin ligands in the treatment of Parkinson's disease. , 2002, Current opinion in pharmacology (Print).

[189]  Y. Mizuno,et al.  Inflammation and infection in Parkinson's disease. , 2006, Histology and histopathology.

[190]  T. Hara,et al.  Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family , 2003, European Journal of Pediatrics.

[191]  K. Lim,et al.  Genetic models of Parkinson disease. , 2009, Biochimica et biophysica acta.

[192]  α-Synuclein and Neuronal Cell Death , 2012, Molecular Neurobiology.

[193]  G. Hitman,et al.  Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. , 2008, Arthritis and rheumatism.

[194]  J. Relton,et al.  Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. , 2008, Brain : a journal of neurology.

[195]  I. Manabe,et al.  Macrophages and islet inflammation in type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[196]  G. Hitman,et al.  Linkage of familial Hibernian fever to chromosome 12p13. , 1998, American journal of human genetics.

[197]  M. D'Andrea,et al.  Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains , 2003, Brain Research.

[198]  U. V. von Andrian,et al.  CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. , 2012, Immunity.

[199]  B. Chromy,et al.  Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. , 1998, Brain research.

[200]  P. Spano,et al.  Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. , 2006, European journal of pharmacology.

[201]  A. Yamada,et al.  Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-alpha-converting enzyme-dependent ectodomain shedding. , 2009, Investigative ophthalmology & visual science.

[202]  C. Dinarello,et al.  IL-37: a new anti-inflammatory cytokine of the IL-1 family. , 2011, European cytokine network.

[203]  P. Hawkins,et al.  Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.

[204]  L. Tartaglia,et al.  Two TNF receptors. , 1992, Immunology today.

[205]  G. Šimić,et al.  nNOS Expression in Reactive Astrocytes Correlates with Increased Cell Death Related DNA Damage in the Hippocampus and Entorhinal Cortex in Alzheimer's Disease , 2000, Experimental Neurology.

[206]  H. Vanderstichele,et al.  An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-α , 2001, Neurochemistry International.

[207]  Gerrit Schlippe,et al.  Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: cytokines, antioxidants and psoriatic skin auto-fluorescence. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[208]  H. Erdem,et al.  Immunopathogenesis of Behçet’s disease with special emphasize on the possible role of antigen presenting cells , 2007, Rheumatology International.

[209]  S. Lorenzl,et al.  Minocycline enhances MPTP toxicity to dopaminergic neurons , 2003, Journal of neuroscience research.

[210]  C. Dodé,et al.  Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). , 2007, Rheumatology.

[211]  Bharat B. Aggarwal,et al.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.

[212]  Ninds Net-Pd Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .

[213]  F. Dammacco,et al.  Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. , 1999, Arthritis and rheumatism.

[214]  J. Stow,et al.  Cytokine secretion in macrophages and other cells: pathways and mediators. , 2009, Immunobiology.

[215]  Y. Fukuda,et al.  Interleukin-13 induces thymus and activation-regulated chemokine (CCL17) in human peripheral blood mononuclear cells. , 2002, Cytokine.

[216]  D. Kastner,et al.  The TNF Receptor-Associated Periodic Syndrome (TRAPS): Emerging Concepts of an Autoinflammatory Disorder , 2002, Medicine.

[217]  C. Nathan,et al.  Shedding of tumor necrosis factor receptors by activated human neutrophils , 1990, The Journal of experimental medicine.

[218]  M. Mattson NF-kappaB in the survival and plasticity of neurons. , 2005, Neurochemical research.

[219]  S. Akira,et al.  Correction: Stat3 Activation Is Responsible for IL-6–Dependent T Cell Proliferation through Preventing Apoptosis: Generation and Characterization of T Cell–Specific Stat3-Deficient Mice , 2015, The Journal of Immunology.

[220]  D. Goeddel,et al.  Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.

[221]  Myung-Shik Lee Cytokine synergism in apoptosis: its role in diabetes and cancer. , 2002, Journal of biochemistry and molecular biology.

[222]  J. Wegiel,et al.  Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease , 2004, Neurobiology of Aging.

[223]  M. D. Turner,et al.  Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion , 2011, Bioscience reports.

[224]  P. Taupin Adult neurogenesis pharmacology in neurological diseases and disorders , 2008, Expert review of neurotherapeutics.

[225]  B. Medoff,et al.  IFN-γ-Inducible Protein 10 (CXCL10) Contributes to Airway Hyperreactivity and Airway Inflammation in a Mouse Model of Asthma1 , 2002, The Journal of Immunology.

[226]  G. Hitman,et al.  Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. , 2009, Arthritis and rheumatism.

[227]  P. Halban,et al.  Cytokine production by islets in health and diabetes: cellular origin, regulation and function , 2010, Trends in Endocrinology & Metabolism.

[228]  Makoto Sawada,et al.  Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.

[229]  C. Jacque,et al.  Identification and topography of neuronal cell populations expressing TNF alpha and IL-1 alpha in response to hippocampal lesion. , 1996, Journal of neuroscience research.

[230]  H. Gendelman,et al.  Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.

[231]  J. Grant-Kels,et al.  Infantile Generalized Pustular Psoriasis Associated With Lytic Lesions of the Bone , 1993, Pediatric dermatology.

[232]  L. Cosmi,et al.  IL-1 and T Helper Immune Responses , 2013, Front. Immunol..

[233]  H. Boddeke,et al.  Neuronal Chemokines: Versatile Messengers In Central Nervous System Cell Interaction , 2007, Molecular Neurobiology.

[234]  H. Gendelman,et al.  CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2007, Journal of Neuroimmunology.

[235]  Anthony H V Schapira,et al.  Neurobiology and treatment of Parkinson's disease. , 2009, Trends in pharmacological sciences.

[236]  J. Toro,et al.  Autoinflammatory diseases: clinical and genetic advances. , 2008, Archives of dermatology.

[237]  J. Trowsdale,et al.  Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function , 2007, Proceedings of the National Academy of Sciences.

[238]  E. Leonard,et al.  Neutrophil attractant/activation protein-1 (NAP-1 [interleukin-8]). , 1990, American journal of respiratory cell and molecular biology.

[239]  D. Huster,et al.  The influence of glycosaminoglycans on IL-8-mediated functions of neutrophils. , 2012, Carbohydrate research.

[240]  V. Bonifati LRRK2 Low-penetrance Mutations (Gly2019Ser) and Risk Alleles (Gly2385Arg)—Linking Familial and Sporadic Parkinson’s Disease , 2007, Neurochemical Research.

[241]  P. Rutgeerts,et al.  Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future , 2013, Alimentary pharmacology & therapeutics.

[242]  P. Mander,et al.  Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.

[243]  Ian Todd,et al.  Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes , 1999, Cell.

[244]  K. Rajarathnam,et al.  Monomeric and Dimeric CXCL8 Are Both Essential for In Vivo Neutrophil Recruitment , 2010, PloS one.

[245]  M. Herrero,et al.  Parkinson's disease and inflammatory changes , 2009, Neurotoxicity Research.

[246]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[247]  R. Shivers,et al.  Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. , 2004, Histology and histopathology.

[248]  S. Barger,et al.  S100β Induction of the Proinflammatory Cytokine Interleukin‐6 in Neurons , 2000, Journal of neurochemistry.

[249]  D J Rowlands,et al.  A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. , 2004, Health technology assessment.

[250]  Juliet M. Taylor,et al.  Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease , 2013, Neurochemistry International.

[251]  R. Goldbach-Mansky,et al.  Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. , 2010, Clinical immunology.

[252]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[253]  D. Goeddel,et al.  Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. , 1999, Science.

[254]  P. Lev,et al.  Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia. , 2010, Experimental hematology.

[255]  Scott Carver,et al.  Cytokine traps: multi-component, high-affinity blockers of cytokine action , 2003, Nature Medicine.

[256]  T. Wright,et al.  Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. , 1999, The Journal of clinical investigation.

[257]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[258]  Tapan P. Patel,et al.  Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death , 2011, Neuron.

[259]  L. Lue,et al.  Involvement of Microglial Receptor for Advanced Glycation Endproducts (RAGE) in Alzheimer's Disease: Identification of a Cellular Activation Mechanism , 2001, Experimental Neurology.

[260]  Richard J Smeyne,et al.  Allopregnanolone Reinstates Tyrosine Hydroxylase Immunoreactive Neurons and Motor Performance in an MPTP-Lesioned Mouse Model of Parkinson's Disease , 2012, PloS one.

[261]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[262]  B. Dewald,et al.  Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate , 2004, Rheumatology International.

[263]  P. Mcgeer,et al.  R-(−)-Deprenyl Inhibits Monocytic THP-1 Cell Neurotoxicity Independently of Monoamine Oxidase Inhibition , 2000, Experimental Neurology.

[264]  M. Turner,et al.  Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. , 1988, Clinical and experimental immunology.

[265]  M. Kumar,et al.  Anti-inflammatory treatments for chronic diseases: a review. , 2013, Inflammation & allergy drug targets.

[266]  L. Moreland Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. , 1999, Cleveland Clinic journal of medicine.

[267]  A. Bakkaloğlu,et al.  Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? , 2003, The Journal of rheumatology.

[268]  A. Fischer,et al.  Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. , 2002, American journal of human genetics.

[269]  A. Osterhaus,et al.  Vγ9Vδ2 T cells recovered from eyes of patients with Behçet's disease recognize non-peptide prenyl pyrophosphate antigens , 2002, Journal of Neuroimmunology.

[270]  H. Loetscher,et al.  Tumor necrosis factor receptors-structure and function , 1992, Immunologic research.

[271]  C. Gabay,et al.  IL‐1, IL‐18, and IL‐33 families of cytokines , 2008, Immunological reviews.

[272]  D. Männel,et al.  The TNF-TNF receptor system. , 2002, Biological chemistry.

[273]  L. Petruzzelli,et al.  Signaling Pathways Involved in IL-8-Dependent Activation of Adhesion Through Mac-11 , 2002, The Journal of Immunology.

[274]  L. Hassman,et al.  Pulmonary Chemokine Expression Is Coordinately Regulated by STAT1, STAT6, and IFN-γ , 2004, The Journal of Immunology.

[275]  M. McDermott,et al.  Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases , 2012, Current opinion in rheumatology.

[276]  S. Rose-John,et al.  The importance of shedding of membrane proteins for cytokine biology. , 2000, European cytokine network.

[277]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[278]  H. Inoko,et al.  Immunology and functional genomics of Behçet's disease , 2003, Cellular and Molecular Life Sciences CMLS.

[279]  Y. Suh,et al.  Minocycline and neurodegenerative diseases , 2009, Behavioural Brain Research.

[280]  G. Bing,et al.  Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.

[281]  C. Jackson,et al.  Western ALS Study Group , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[282]  M. Giedlin,et al.  IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. , 1995, Journal of immunology.

[283]  C. Hogaboam,et al.  Chemokines in allergic aspergillosis--from animal models to human lung diseases. , 2006, Inflammation & allergy drug targets.

[284]  M. Humbert,et al.  Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. , 1999, Journal of immunology.

[285]  H. Ellingsgaard,et al.  Low Concentration of Interleukin-1β Induces FLICE-Inhibitory Protein–Mediated β-Cell Proliferation in Human Pancreatic Islets , 2006, Diabetes.

[286]  J. Paović,et al.  Behcet's Disease: Systemic and Ocular Manifestations , 2013, BioMed research international.

[287]  J. Sanderson,et al.  Role of γδ T cells in pathogenesis and diagnosis of Behçet's disease , 1996, The Lancet.

[288]  E. Borroni,et al.  Shaping the gradient by nonchemotactic chemokine receptors , 2009, Cell adhesion & migration.

[289]  J. Rogers,et al.  Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. , 2000, Brain research. Molecular brain research.

[290]  C. Browning,et al.  Signalling by CXC‐chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL‐8 and GROα , 1999, British journal of pharmacology.

[291]  D. Wakefield,et al.  The role of cytokines in the pathogenesis of inflammatory eye disease. , 1992, Cytokine.

[292]  A. Hamzaoui,et al.  Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. , 2004, Journal of autoimmunity.

[293]  T. Klockgether,et al.  Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[294]  C. Montecucco,et al.  Role of chemokines and chemokine receptors in regulating specific leukocyte trafficking in the immune/inflammatory response. , 2003, Clinical and experimental rheumatology.

[295]  W. Zou,et al.  Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. , 2007, American journal of physiology. Cell physiology.

[296]  G. Hitman,et al.  Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients. , 2011, Cellular immunology.

[297]  A. Członkowska,et al.  Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. , 2004, International immunopharmacology.

[298]  Serdar Balci,et al.  Phenotype 2 Familial Mediterranean Fever: Evaluation of 22 Case Series and Review of the Literature on Phenotype 2 FMF , 2013, Renal failure.

[299]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[300]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.

[301]  Shunichiro Shinagawa,et al.  Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease. , 2013, Biochemical and biophysical research communications.

[302]  F. L. Saux,et al.  Identification and topography of neuronal cell populations expressing; TNFα and IL‐1α in response to hippocampal lesion , 1996 .

[303]  G. D'Haens,et al.  Recent developments in the treatment of inflammatory bowel disease , 2013, Journal of digestive diseases.

[304]  J. Flier,et al.  Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation , 2001, The Journal of pathology.

[305]  P. Toghill,et al.  Familial Hibernian fever. , 1982, The Quarterly journal of medicine.

[306]  R. Dwek,et al.  Glycosylation of interleukin-6 purified from normal human blood mononuclear cells. , 1992, European journal of biochemistry.

[307]  T. Jin,et al.  Fluorescence Resonance Energy Transfer Imaging Reveals that Chemokine-Binding Modulates Heterodimers of CXCR4 and CCR5 Receptors , 2008, PloS one.

[308]  H. Erdem,et al.  Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations? , 2006, Rheumatology International.

[309]  S. Akira,et al.  Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. , 1998, Journal of immunology.

[310]  R. Maizels,et al.  IL-6 controls susceptibility to helminth infection by impeding Th2 responsiveness and altering the Treg phenotype in vivo , 2013, European journal of immunology.

[311]  P. Magistretti,et al.  The role of astroglia in neuroprotection , 2009, Dialogues in clinical neuroscience.

[312]  D. Sillence,et al.  Gene localization for an autosomal dominant familial periodic fever to 12p13. , 1998, American journal of human genetics.

[313]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[314]  P. Gregersen,et al.  An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. , 2009, The New England journal of medicine.

[315]  S. Davis,et al.  What can rodent models tell us about cognitive decline in alzheimer’s disease? , 2003, Molecular Neurobiology.

[316]  S. Rose-John,et al.  Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. , 1998, Blood.

[317]  T. Imai,et al.  Chemokines as Novel Therapeutic Targets for Inflammatory Bowel Disease , 2009, Annals of the New York Academy of Sciences.

[318]  Sulagna Das,et al.  Inflammation: A new candidate in modulating adult neurogenesis , 2008, Journal of neuroscience research.

[319]  J. Ahluwalia Immunotherapy in inflammatory bowel disease. , 2012, The Medical clinics of North America.

[320]  J. Bradley,et al.  TNF‐mediated inflammatory disease , 2008, The Journal of pathology.

[321]  A. Schapira Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease , 2009, Neurology.

[322]  G. Firestein,et al.  Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist , 2004, The Lancet.

[323]  M. O’Banion,et al.  Regulation of prostaglandin E2 synthesis after brain irradiation. , 2005, International journal of radiation oncology, biology, physics.

[324]  J. Natvig,et al.  The Chemokines CCL5, CCL2 and CXCL12 Play Significant Roles in the Migration of Th1 Cells into Rheumatoid Synovial Tissue , 2003, Scandinavian journal of immunology.

[325]  Gregory Jicha,et al.  Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[326]  L. O’Neill,et al.  The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress , 2008, Immunological reviews.